After reviewing the available body of evidence, the Centers for Disease Control (CDC) in the USA have concluded that a causal relationship exists between prenatal Zika virus infection and microcephaly and other serious brain anomalies. Cases of locally-transmitted Zika virus are still being reported in Brazil and most of its neighbouring countries.
This statement is a CEU response to a study published in the BMJ titled Low dose oestrogen combined oral contraception and risk of pulmonary embolism, stroke, and myocardial infarction in five million French women: cohort study.
This CEU Statement provides guidance to healthcare professionals in response to a letter circulated by MSD to healthcare professionals in the UK regarding a small number of reports of Nexplanon contraceptive implants inadvertently inserted into blood vessels.
The Medicines and Healthcare products Regulatory Agency (MHRA) recently launched a toolkit for healthcare professionals (HCPs) regarding sodium valproate in order to communicate its teratogenic effects. The CEU recommends that all HCPs be prepared to provide information about and access to effective contraception for women who have undergone treatment with valproate-related medicines.
A Danish database study, published in the BMJ on 6/1/16  finds no significant increase in the overall risk of major birth defects amongst babies whose mothers used oral contraceptives (OC) in the three months prior to conception or in early pregnancy.
Essure® is a form of female sterilisation which involves the hysteroscopic insertion of flexible micro-inserts into the proximal section of the fallopian tubes and is undertaken without general anaesthesia.
A large observational study from the United States found that the risk of unintended pregnancy after Essure sterilisation was similar to that after surgical sterilisation. However just over 2% of women who had Essure sterilisation required a further operation related to the sterilisation procedure within a year.
The CEU supports the self administration of Sayana Press® because of its potential benefits to women and services. It offers women greater choice and more autonomy over their contraception and fertility.